These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16883086)

  • 21. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
    Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
    Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
    Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
    Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
    Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
    Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
    Leszek J; Małyszczak K; Janicka B; Kiejna A; Wiak A
    Med Sci Monit; 2003 Nov; 9(11):CR484-8. PubMed ID: 14586274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.
    Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Trenkwalder C; Brechlin P; Rüther E; Kornhuber J; Otto M; Wiltfang J
    J Neural Transm (Vienna); 2006 Nov; 113(11):1771-8. PubMed ID: 16906356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
    Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
    Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin.
    Lang V; Zille M; Infante-Duarte C; Jarius S; Jahn H; Paul F; Ruprecht K; Pina AL
    J Neurol Sci; 2017 Apr; 375():123-128. PubMed ID: 28320113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor.
    Ferreira D; Westman E; Eyjolfsdottir H; Almqvist P; Lind G; Linderoth B; Seiger A; Blennow K; Karami A; Darreh-Shori T; Wiberg M; Simmons A; Wahlund LO; Wahlberg L; Eriksdotter M
    J Alzheimers Dis; 2015; 43(3):1059-72. PubMed ID: 25147108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in cerebrospinal fluid nerve growth factor levels during chick embryonic development.
    Mashayekhi F; Azari M; Moghadam LM; Yazdankhah M; Naji M; Salehi Z
    J Clin Neurosci; 2009 Oct; 16(10):1334-7. PubMed ID: 19581095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.
    Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S
    Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
    Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
    Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology.
    Miners JS; Kehoe PG; Love S; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2019 Sep; 11(1):81. PubMed ID: 31521199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
    Chakraborty A; Chatterjee M; Twaalfhoven H; Del Campo Milan M; Teunissen CE; Scheltens P; Fontijn RD; van Der Flier WM; de Vries HE
    Alzheimers Res Ther; 2018 Jun; 10(1):58. PubMed ID: 29933741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid.
    Chong JK; Miller BE; Ghanbari HA
    Life Sci; 1990; 47(13):1163-71. PubMed ID: 2122149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
    Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
    Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.